EMBECTA CORP. Other General Expense
EMBECTA CORP. (EMBC) reported Other General Expense of $65.40 million for the 12-month period ending 2025-09-30, per its 10-K filed 2025-11-25.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OtherGeneralExpense · last filed 2025-11-25
- EMBECTA CORP. other general expense for the quarter ending 2025-09-30 was $10.50M, a 66.13% decline year-over-year.
- EMBECTA CORP. other general expense for the quarter ending 2025-06-30 was $14.30M, a 49.11% decline year-over-year.
- EMBECTA CORP. other general expense for the quarter ending 2025-03-31 was $13.60M, a 61.69% decline year-over-year.
- EMBECTA CORP. other general expense for the quarter ending 2024-12-31 was $27.00M, a 9.70% decline year-over-year.
- EMBECTA CORP. other general expense for fiscal 2025 was $65.40M, a 47.47% decline from fiscal 2024.
- EMBECTA CORP. other general expense for fiscal 2024 was $124.50M, a 25.25% increase from fiscal 2023.
- EMBECTA CORP. other general expense for fiscal 2023 was $99.40M, a 122.37% increase from fiscal 2022.
- EMBECTA CORP. other general expense for fiscal 2022 was $44.70M, a 831.25% increase from fiscal 2021.
| Period end | Other General Expense 3 month | Other General Expense 6 month | Other General Expense 9 month | Other General Expense 12 month |
|---|---|---|---|---|
| 2025-09-30 | $10.50M derived: 10-K 12 month − 10-Q 9 month · filed 2025-11-25 | $24.80M derived: sum of 2 quarters · filed 2025-11-25 | $38.40M derived: sum of 3 quarters · filed 2025-11-25 | $65.40M 10-K · filed 2025-11-25 |
| 2025-06-30 | $14.30M 10-Q · filed 2025-08-08 | $27.90M derived: sum of 2 quarters · filed 2025-08-08 | $54.90M 10-Q · filed 2025-08-08 | $85.90M derived: sum of 4 quarters · filed 2025-11-25 |
| 2025-03-31 | $13.60M 10-Q · filed 2025-05-09 | $40.60M 10-Q · filed 2025-05-09 | $71.60M derived: sum of 3 quarters · filed 2025-11-25 | $99.70M derived: sum of 4 quarters · filed 2025-11-25 |
| 2024-12-31 | $27.00M 10-Q · filed 2025-02-06 | $58.00M derived: sum of 2 quarters · filed 2025-11-25 | $86.10M derived: sum of 3 quarters · filed 2025-11-25 | $121.60M derived: sum of 4 quarters · filed 2025-11-25 |
| 2024-09-30 | $31.00M derived: 10-K 12 month − 10-Q 9 month · filed 2025-11-25 | $59.10M derived: sum of 2 quarters · filed 2025-11-25 | $94.60M derived: sum of 3 quarters · filed 2025-11-25 | $124.50M 10-K · filed 2025-11-25 |
| 2024-06-30 | $28.10M 10-Q · filed 2025-08-08 | $63.60M derived: sum of 2 quarters · filed 2025-08-08 | $93.50M 10-Q · filed 2025-08-08 | $127.70M derived: sum of 4 quarters · filed 2025-11-25 |
| 2024-03-31 | $35.50M 10-Q · filed 2025-05-09 | $65.40M 10-Q · filed 2025-05-09 | $99.60M derived: sum of 3 quarters · filed 2025-11-25 | $127.60M derived: sum of 4 quarters · filed 2025-11-25 |
| 2023-12-31 | $29.90M 10-Q · filed 2025-02-06 | $64.10M derived: sum of 2 quarters · filed 2025-11-25 | $92.10M derived: sum of 3 quarters · filed 2025-11-25 | $119.00M derived: sum of 4 quarters · filed 2025-11-25 |
| 2023-09-30 | $34.20M derived: 10-K 12 month − 10-Q 9 month · filed 2025-11-25 | $62.20M derived: sum of 2 quarters · filed 2025-11-25 | $89.10M derived: sum of 3 quarters · filed 2025-11-25 | $99.40M 10-K · filed 2025-11-25 |
| 2023-06-30 | $28.00M 10-Q · filed 2024-08-09 | $54.90M derived: sum of 2 quarters · filed 2024-08-09 | $65.20M 10-Q · filed 2024-08-09 | $86.40M derived: sum of 4 quarters · filed 2024-12-11 |
| 2023-03-31 | $26.90M 10-Q · filed 2024-05-09 | $37.20M 10-Q · filed 2024-05-09 | $58.40M derived: sum of 3 quarters · filed 2024-12-11 | $66.10M derived: sum of 4 quarters · filed 2024-12-11 |
| 2022-12-31 | $10.30M 10-Q · filed 2024-02-09 | $31.50M derived: sum of 2 quarters · filed 2024-12-11 | $39.20M derived: sum of 3 quarters · filed 2024-12-11 | $46.60M derived: sum of 4 quarters · filed 2024-12-11 |
| 2022-09-30 | $21.20M derived: 10-K 12 month − 10-Q 9 month · filed 2024-12-11 | $28.90M derived: sum of 2 quarters · filed 2024-12-11 | $36.30M derived: sum of 3 quarters · filed 2024-12-11 | $44.70M 10-K · filed 2024-12-11 |
| 2022-06-30 | $7.70M 10-Q · filed 2023-08-08 | $15.10M derived: sum of 2 quarters · filed 2023-08-08 | $23.50M 10-Q · filed 2023-08-08 | $26.20M derived: sum of 4 quarters · filed 2023-11-29 |
| 2022-03-31 | $7.40M 10-Q · filed 2023-05-12 | $15.80M 10-Q · filed 2023-05-12 | $18.50M derived: sum of 3 quarters · filed 2023-11-29 | $20.60M derived: sum of 4 quarters · filed 2023-11-29 |
| 2021-12-31 | $8.40M 10-Q · filed 2023-02-14 | $11.10M derived: sum of 2 quarters · filed 2023-11-29 | $13.20M derived: sum of 3 quarters · filed 2023-11-29 | $13.20M derived: sum of 4 quarters · filed 2023-11-29 |
| 2021-09-30 | $2.70M derived: 10-K 12 month − 10-Q 9 month · filed 2023-11-29 | $4.80M derived: sum of 2 quarters · filed 2023-11-29 | $4.80M derived: sum of 3 quarters · filed 2023-11-29 | $4.80M 10-K · filed 2023-11-29 |
| 2021-06-30 | $2.10M 10-Q · filed 2022-08-15 | $2.10M derived: sum of 2 quarters · filed 2022-08-15 | $2.10M 10-Q · filed 2022-08-15 | |
| 2021-03-31 | $0.00 10-Q · filed 2022-05-13 | $0.00 10-Q · filed 2022-05-13 | ||
| 2020-09-30 | $0.00 10-K · filed 2022-12-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TREACE MEDICAL CONCEPTS, INC. (TMCI) | United States | $0.297B | -4.32 |
| Mobia Medical, Inc. (MOBI) | United States | $0.293B | |
| TriSalus Life Sciences, Inc. (TLSI) | United States | $0.283B | -9.92 |
| SHOULDER INNOVATIONS, INC. (SI) | United States | $0.355B | |
| Orchestra BioMed Holdings, Inc. (OBIO) | United States | $0.356B | -4.39 |
| Cytosorbents Corp (CTSO) | United States | $0.274B | -1.29 |
| ORASURE TECHNOLOGIES INC (OSUR) | United States | $0.272B | -6.26 |
| Anika Therapeutics, Inc. (ANIK) | United States | $0.272B | -51.71 |
| Orthofix Medical Inc. (OFIX) | $0.373B | ||
| InfuSystem Holdings, Inc (INFU) | United States | $0.253B | 22.52 |